New Treatment for MOG Antibody Condition
Official title: Novel immunotherapy against MOG antibody disease
Funded at Evoq Therapeutics, INC. · NIH-11136993 · Data updated 2026-11-12
This research is developing a new, targeted treatment for people living with MOG antibody disease, a rare neurological condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Evoq Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | July 15, 2022 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $988,943 |
| NIH project number | 5R44TR005293-03 |
| Project ID | NIH-11136993 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is ultimately for individuals diagnosed with Myelin Oligodendrocyte Glycoprotein (MOG) antibody disease who are seeking new treatment options.
✕Less likely to help
Patients without MOG antibody disease would not directly benefit from this specific treatment approach.
What this research studies
MOG antibody disease (MOGAD) is a rare neurological condition that can cause vision loss, spinal cord issues, and seizures. Current treatments often involve steroids and immunosuppressants, which can have side effects and may not prevent frequent relapses. This project aims to create a new, more targeted treatment using tiny particles called NanoDiscs. These NanoDiscs are designed to deliver specific signals to the immune system, helping it to stop attacking the body's own MOG protein. The goal is to develop a treatment that specifically targets the cause of MOGAD, offering a better option for patients.
Why it matters
Potential benefit: If successful, this new approach could offer MOGAD patients a more targeted treatment with fewer side effects and potentially reduce debilitating relapses compared to current therapies.
How similar studies have gone: Preliminary data in animal models of similar autoimmune conditions, like experimental autoimmune encephalomyelitis and type 1 diabetes, has shown promising results with this NanoDisc technology.
Where this research is happening
-
Evoq Therapeutics, INC.
Ann Arbor, United States Active
Researchers
- Principal investigator: Daniel, Weston — Evoq Therapeutics, INC.
- Study coordinator: Daniel, Weston
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.